Navigation Links
Pradaxa® (dabigatran etexilate mesylate) Capsules Now on Formulary at Nation's Top Heart Hospitals
Date:7/21/2011

RIDGEFIELD, Conn., July 21, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that Pradaxa® (dabigatran etexilate mesylate) capsules has been added to hospital formularies at 49 of the top 50 cardiology and heart surgery hospitals, as ranked by U.S. News & World Report's Best Hospitals 2011-2012, published online on July 19.  PRADAXA is approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).(1)

Atrial fibrillation (AFib), characterized by an irregular heartbeat,(2) increases the risk of stroke nearly five times.(3)  Approximately 80 percent of U.S. adults living with AFib are age 65 or older,(4) and many have other conditions, such as diabetes or hypertension, that further increase the risk of stroke.(2)  A Medicare claims database analysis showed that approximately 70 percent of NVAF patients are hospitalized each year.(5) Overall, annual hospital admissions for NVAF, as a primary or secondary diagnosis, total nearly 2.7 million or approximately seven percent of all hospital admissions in the U.S.(6)  

"At Boehringer Ingelheim, patients are our first priority and we've worked with hospitals across the country to support the addition of PRADAXA to formularies," said Wa'el Hashad, vice president, cardiovascular and metabolic disorders marketing, Boehringer Ingelheim Pharmaceuticals, Inc. "In the first seven months after approval, more than 250,000 patients were prescribed PRADAXA, suggesting this important treatment has been well received in the everyday clinical setting to reduce the risk of stroke in patients with non-valvular atrial fibrillation."

PRADAXA is now included on formularies that insure about 90 percent of covered lives in the U.S.(7)  For those patients who may not otherwise be able to afford treatment, BIPI offers patient assista
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)
2. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
3. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
4. Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
5. Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration
6. Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment
7. FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
8. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
9. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
10. American Oriental Bioengineerings Jinji Capsules and Boke Nasal Spray Designated Among Chinas Top Branded Drugs of 2009
11. Roxane Laboratories, Inc. Announces the Launch of Mycophenolate Mofetil 250mg Capsules and 500mg Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Researchers have pioneered ... images. The new technology, called Virtual Finger, allows ... structures like neurons and synapses using the flat ... technology makes 3D imaging studies orders of magnitude ... an unprecedented level across many areas of experimental ...
(Date:7/10/2014)... July 10, 2014 Understanding the need ... cell lines, and the gap that currently exists in ... expand its industry-leading portfolio of validated ion channel and ... channel-expressing cell lines, as ion channels control many critical ... this activity creates the potential to treat a variety ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded for ... a second treatment cup to help prevent and smooth skin ... thinner on the edges for a softer contact with the ... surfaces on the face, neck and décolleté. Choose to use ... such as the cheeks and neck, or opt for the ...
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- ... and interpretation, today announced an agreement with ... analytics for Lineagen,s NextStep Dx PLUS.  ... neurodevelopmental and neurological disorders, currently offers FirstStep ... (CMA) testing service used by healthcare providers ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... Good Start Genetics, an innovative molecular diagnostics ... carrier screening in clinical practice, will announce later ... its proprietary next-generation DNA sequencing platform. In the ... of the American Society for Reproductive Medicine, Good ...
... BRUSSELS, IRVINE, California, and AMSTERDAM, October 18, 2011 ... diagnostics company, today announced the completion of patient registration for ... N ode negative and 1-3 positive lymph node ... T rial) study. More than 6,600 patients in 111 institutions ...
... pleased to announce the full agenda for CMAC 2011 ... being held December 6-7, 2011 in Philadelphia, PA. The ... Solutions, delivers pre- and post-launch strategies, dynamic programming and ... by conference chairman, Robert Besthof, Vice President, Commercial Lead, ...
Cached Biology Technology:Good Start Genetics™ Announces Validation Results for its Next-Generation DNA Sequencing Platform for Genetic Disorder Carrier Screening 2Good Start Genetics™ Announces Validation Results for its Next-Generation DNA Sequencing Platform for Genetic Disorder Carrier Screening 3Good Start Genetics™ Announces Validation Results for its Next-Generation DNA Sequencing Platform for Genetic Disorder Carrier Screening 4EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study 2EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study 3EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study 4EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study 5Full Agenda Announced for CMAC 2011 - CBI'S 2nd Annual Commercialization and Market Access Congress 2
(Date:7/10/2014)... CORAL SPRINGS, Florida , July 1, 2014 ... smart wallets pave way for convenience and improved security: NXT-ID, ... Google Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... ) and MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: ... market, is pleased to announce that the second series of ...
(Date:7/10/2014)... 2, 2014 It is a great honor ... appointment of the world-renowned Thoracic and Cardiovascular surgeon, Mark ... Dr. Ginsburg, with over 34 years of experience, ... and Good Samaritan Regional Medical Center. Dr. Ginsburg has ... 1980,s and is considered an expert in the implantation ...
(Date:7/10/2014)... According to the new market research report, ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile Devices, ... and Geography - Global Trends & Forecasts to 2014 ... Market is projected to cross $14.35 Billion by 2020, ... to 2020. Browse more than 78 market ...
Breaking Biology News(10 mins):Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... Department of Energy (DOE),s Lawrence Berkeley National Laboratory (Berkeley ... ester transfer protein (CETP) mediates the transfer of cholesterol ... density lipoproteins (LDLs). These findings point the way to ... inhibitors that could help prevent the development of heart ...
... Pennsylvania State University College of Medicine, Hershey, Pennsylvania have ... growth factor receptor (OGFr), which mediates the inhibitory action ... a key to understanding the progression and treatment of ... cells that were molecularly engineered to have a reduced ...
... 2012, Cleveland: With 1 in 5 overweight Americans suffering ... nutritional and lifestyle habits of overweight adults, finding that ... cause further kidney damage. The study findings, published ... Obesity , came from an analysis of food choices ...
Cached Biology News:How good cholesterol turns bad 2How good cholesterol turns bad 3A breakthrough in understanding the biology and treatment of ovarian cancer 2A breakthrough in understanding the biology and treatment of ovarian cancer 3Study says overweight Americans may risk kidney damage when attempting weight loss 2
SHEEP ANTI DEHYDROEPIANDROSTERONE...
MOUSE ANTI POLY (ADP-RIBOSE) Immunogen: Purified poly (ADP-ribose) polymer, 10-50 unit chain length...
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
... (1997) • Contains short but ... & molecular biology, arranged under ... give details of biochemical substances ... they are involved and define ...
Biology Products: